A phase I, multi-center, open label, dose escalation trial of safety and pharmacokinetics of intravenous PR-104 given every 3 weeks in patients with solid tumours

Trial Profile

A phase I, multi-center, open label, dose escalation trial of safety and pharmacokinetics of intravenous PR-104 given every 3 weeks in patients with solid tumours

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs PR 104 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Apr 2008 Status changed from recruiting to in progress according to ClinicalTrials.gov.
    • 09 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top